Atara Biotherapeutics (ATRA) Cost of Revenue (2023 - 2026)

Atara Biotherapeutics has reported Cost of Revenue for 4 years, with the latest figure at $124000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 99.39% year-over-year to $124000.0; the trailing twelve-month figure through Mar 2026 stood at $897000.0 (down 97.73% YoY), and the FY2025 full-year result was $21.2 million, up 0.97% from the prior year.
• Cost of Revenue for Q1 2026 stood at $124000.0, up from $104000.0 in the prior quarter.
• The five-year high for Cost of Revenue was $20.4 million in Q1 2025, with the low at $104000.0 in Q4 2025.
• Historically, Cost of Revenue has averaged $3.9 million across 4 years, with a median of $2.6 million in 2023.
• Annual changes were most pronounced in 2025 — Cost of Revenue surged 929.67% — and 2026, when it tumbled 99.39%.
• Atara Biotherapeutics' Cost of Revenue stood at $3.2 million in 2023, then surged by 115.03% to $6.8 million in 2024, then tumbled by 98.47% to $104000.0 in 2025, then grew by 19.23% to $124000.0 in 2026.
• The last three Cost of Revenue figures came in at $124000.0 (Q1 2026), $104000.0 (Q4 2025), and $115000.0 (Q3 2025), per Business Quant data.